Breast Cancer
Triple-negative breast cancer is considered one of the most difficult to treat breast cancers, with few treatment options, but finally a breakthrough study shows progress by extending patient survival. Read More ›
Metastatic estrogen receptor (ER)-positive breast cancer responds well to anti-ER therapies, but eventually resistance occurs and the drugs fail to work. A new study presented at the 2018 AACR meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›
This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer. Read More ›